Combined treatment of the experimental human papilloma virus-16-positive cervical and head and neck cancers with cisplatin and radioimmunotherapy targeting viral E6 oncoprotein

BACKGROUND: Human papilloma virus (HPV) is implicated in >99% of cervical cancers and ∼40% of head and neck squamous cell carcinoma (HNSCC). We previously targeted E6 oncogene with (188)Rhenium-labelled monoclonal antibody (mAb) C1P5 to HPV16 E6 in cervical cancer and HNSCC. Intranuclear E6 can b...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, M, Wang, X G, Jiang, Z, Phaeton, R, Koba, W, Goldberg, G L, Casadevall, A, Dadachova, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590678/
https://www.ncbi.nlm.nih.gov/pubmed/23385729
http://dx.doi.org/10.1038/bjc.2013.43

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590678/
https://www.ncbi.nlm.nih.gov/pubmed/23385729
http://dx.doi.org/10.1038/bjc.2013.43

Ejemplares similares